News & Media

Results of First Half of 2011

16 September 2011, Sophia Antipolis, France

MEDIAN Technologies publishes its 2011 half-yearly results today for the period ending on 30th June 2011. Those results were ended by the Board of Directors on September 16th, 2011

In €K, non-audited turnover

H1 2011

H1 2010

Turnover

Other products*

Total operating revenue

353

516

869

556

28

584

Operating profit

(2 026)

(1 792)

Earnings

(348)

(281)

Exceptional items

74

(99)

Corporation tax

326

ND

Net income

(1 974)

(2 172)

Cash

8 778

2 968

 * of which €445K in transfers of expenditure relating to capital increases in May 2011 that were deductible from issue premiums

Turnover for MEDIAN Technologies came to €353K during the first half of 2011. This breaks down to €314K for routine radio-oncology activity, and €39K for pharmaceutical activity in the form of clinical trials. Operating expenses mainly comprise payroll expenses and come to €1,798K, while other purchases and external expenses amounted to €982K.

Major strategic partners’ negotiations (with Canon Inc. in July 2011, with KLSC announced today, and with others potential partners in discussion with MEDIAN Technologies) that kept the management team busy to the detriment of the short term marketing activities are likely to have a positive impact on future plans.

Commercial activity is expected to grow in the second half-year. After the signature of 4 first contracts with 3 top Pharmaceutical companies, the company is in active discussion leading to the signature of new contracts. Furthermore, MEDIAN Technologies has recently recruited a Pharma Business Development Vice President.

A solid financial situation

On 30th June 2011, the company’s cash achieved 8.7M€ highlighting 4.9M€ of liabilities, partly thanks to 9.5M€ raised (net of share issuance costs) during the admission on NYSE Alternext last May. In July 2011, MEDIAN Technologies reinforced one more time its cash and shareholders’ capital with a  2.0M€ capital increase reserved to Canon Inc.

Signature of a partnership with KLSC (Kuwait Life Science Company) in order to bring MEDIAN Technologies to the Middle East

MEDIAN Technologies has signed a strategic partnership with KLSC (Kuwait Life Science Company), a branch of National Technology Enterprises Company (NTEC), the Kuwaiti investment company. KLSC invests in technological-innovative companies in the Health sector. This agreement related to KLSC’s input into MEDIAN Technologies’ capital funds as it enters the stock market, is intended to establish MEDIAN Technologies in the Middle East and North Africa.  This partnership with a local actor will have a significant impact on MEDIAN Technologies in this area. A first step has been made by recruiting a common Regional Officer.

Operational establishment of strategic agreement with Canon Inc.

In July 2011, MEDIAN Technologies signed a strategic agreement with Canon Inc to widely distribute its solutions as well as to co-develop and bring to market new products and services.  This agreement was signed alongside Canon Inc’s acquisition of a 15% stake in MEDIAN Technologies’s capital, for a sum of €8.6M.

This partnership is being established in three ways:

  1. The co-development of new products: Several experts from Canon Inc. join the French teams at MEDIAN Technologies to collaborate on Computer Aided Diagnostics technology (CAD).
  2. The implementation of MEDIAN Technologies solutions on cloud computing infrastructures of CANON for hospitals and the pharmaceutical industry in the form of SAAS – Software as a Service.
  3. A distribution agreement in Asia, whose details are under discussion.

Expected growth in commercial activity in the second half-year: various discussions are taking place with pharmaceutical companies, as well as the recruitment of a regional manager

After the signature of 4 first contracts with 3 top Pharmaceutical companies for phase 1/11 clinical trials and a companion test investigation contract, the company is in active discussion leading to the signature of new contracts.

 In order to accelerate the marketing of its solutions, MEDIAN Technologies has recently recruited Jérôme Windsor as Pharma Business Development Vice President.  Jérôme Windsor is the former Vice President of commercial development and partners at UnitedHealth Group and has over 15 years’ experience as European development manager at Cerep and as a consultant at Pricewaterhousecoopers and Accenture.  His considerable knowledge of the strategic issues at stake as well as of the partners at the pharmaceutical companies and of the CROs represents a substantial asset for MEDIAN Technologies.

MEDIAN Technologies CEO Fredrik Brag said of the developments: « Presently, MEDIAN Technologies is working on a wealth of projects.  We are putting into place strategic partnerships that amount to some fantastic opportunities to accelerate the company’s development.  Our partnership with Canon Inc is being bedded in, and represents a great move forward in our history.  Today, our commercial pipeline is significant, and our marketing activity is expected to accelerate in the second year-half.”

About Median Technologies.

Median Technologies develops medical imaging software and services dedicated to oncology clinical trials, cancer screening, and clinical practice. Median Technologies standardizes and automates the interpretation of medical images in oncology to optimize the diagnosis of cancer patients and the assessment of their response to therapy. Median serves two primary markets: drug development and patient care. Median has a strategic partnership with the world’s largest CRO (Contract Research Organization) to offer integrated imaging services for clinical trials to biopharma sponsors worldwide, and a strategic partnership with Canon to develop new imaging technologies, and to address the patient care market.

Founded in 2002, Median Technologies is based in Sophia-Antipolis, France, and has a US subsidiary in Boston. Median has a global reach and actively works with clinical sites located in Asia, Europe, North and South America, and Australia.

Median has received the label “Innovative company” by the BPI and is listed on Euronext Paris’ Alternext market (ISIN: FR0011049824, ticker: ALMDT). The company is eligible for the PEA PME SME equity savings plan setup.

“We are committed to the improvement of cancer patient outcomes through innovation in medical imaging and quality execution for better screening, diagnosis, and monitoring of patients.”

Contacts

MEDIAN Technologies

Fredrik Brag
CEO
+33 4 92 90 65 82
fredrik.brag@mediantechnologies.com

Actifin (Investors)

Ghislaine Gasparetto
+33 1 56 88 11 11
ggasparetto@actifin.fr

Alizé RP (Press)

Caroline Carmagnol
Wendy Rigal

+33 1 44 54 36 66
median@alizerp.com